Dr Catherine Beech, CEO at Exonate and Dr Pete Adamson, CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Diabetic retinal disease, termed diabetic retinopathy (DR), is a significant risk factor for people with Type I or II diabetes, and one that increases […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!